CCO Slideset

Session VII: Malignant Stem Cells as Targets in Oncology

Source: 6th International Symposium on Translational Research in Oncology

Session VII: Malignant Stem Cells as Targets in Oncology

Program Directors:

Dennis J. Slamon, MD, PhD
John Crown, MD, MPH

Faculty:

Hasan Korkaya, PhD

CME CREDIT INFORMATION

Release Date: 01/28/08

Expiration Date: 01/27/09

Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss the role of Wnt signaling in cancer and cancer stem cells
Describe the action of transforming growth factor beta in normal and malignant cells
Explain the therapeutic use of PARP inhibition in cancer treatment
Summarize the effect of HER2 overexpression on cancer stem cell growth

Topics covered include:

Session VII: Malignant Stem Cells as Targets in Oncology

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.